Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study

Glycemic Control

Associations between second-line glucose-lowering combination therapies with metformin and HbA_1c , body weight, quality of life, hypoglycaemic events, and glucose-lowering treatment intensification: the DISCOVER study

Diabetes Obes Metab

Khunti K, Charbonnel B, Cooper A, Gomes MB, Ji L, Leigh P, Nicolucci A, Rathmann W, Shestakova MV, Siddiqui A, Tang F, Watada H, Chen H, DISCOVER investigators.

doi: 10.1111/dom.14400

COMMENTED

Diabetes - GeneralType 2 Diabetes

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

BMJ

Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S

doi: 10.1136/bmj.k2693.

COMMENTED

Type 2 Diabetes

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme

Diabetes Obes Metab.

Nicolucci A, Charbonnel B, Gomes MB, Khunti K, Kosiborod M, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Razufa J, Fenici P, Hammar N, Surmont F, Tang F, Pocock S

doi: 10.1111/dom.13830.

Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalisation and mortality records.

Diabetes Obes Metab.

Zghebi SS, Steinke DT, Rutter MK, Emsley RA, Ashcroft DM

doi: 10.1111/dom.12692.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia

Diabetes Res Clin Pract.

Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW

doi: 10.1016/j.diabres.2016.12.004.

COMMENTED

Type 2 Diabetes

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study

BMJ.

Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, Platt RW, Bouganim N, Azoulay L

doi: 10.1136/bmj.k4880.

COMMENTED

Type 2 Diabetes

Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes

JAMA Netw Open.

O’Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT

doi: 10.1001/jamanetworkopen.

COMMENTED

Type 2 Diabetes

Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

doi: 10.2337/dc19-2535.

COMMENTED

Obesity and Bariatric Surgery

Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records

★ 2 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol

Katsoulis M, Lai AG, Diaz-Ordaz K, Gomes M, Pasea L, Banerjee A, Denaxas S, Tsilidis K, Lagiou P, Misirli G, Bhaskaran K, Wannamethee G, Dobson R, Batterham RL, Kipourou DK, Lumbers RT, Wen L, Wareham N, Langenberg C, Hemingway H

doi: 10.1016/S2213-8587(21)00207-2

Related content

Associations between second-line glucose-lowering combination therapies with metformin and HbA1c , body weight, quality of life, hypoglycaemic events, and glucose-lowering treatment intensification: the DISCOVER study

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme

Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalisation and mortality records.

Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study

Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes

Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users

Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records

Associations between second-line glucose-lowering combination therapies with metformin and HbA_1c , body weight, quality of life, hypoglycaemic events, and glucose-lowering treatment intensification: the DISCOVER study